Indaptus Therapeutics (INDP) director David Natan reports zero holdings

Rhea-AI Filing Summary

Indaptus Therapeutics, Inc. director David Natan filed an initial ownership report stating that he currently holds no shares of the company. The filing shows that he has no beneficial ownership of non-derivative or derivative securities of Indaptus as of the event date, and his position is reported as a director filing on his own behalf.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

NATAN DAVID

(Last) (First) (Middle)

C/O INDAPTUS THERAPEUTICS, INC.

3 COLUMBUS CIRCLE 15TH FLOOR

(Street)

NEW YORK NY 10019

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026

3. Issuer Name and Ticker or Trading Symbol
Indaptus Therapeutics, Inc. [ INDP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities are beneficially owned.	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ David Natan	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the latest Form 3 for INDP show about David Natan?

The Form 3 shows that director David Natan reports no securities beneficially owned in Indaptus Therapeutics, Inc.

Does the INDP director on this Form 3 own any Indaptus shares?

No. The filing states "No securities are beneficially owned" and lists 0 securities beneficially owned on a direct basis.

What is David Natan’s relationship to Indaptus Therapeutics (INDP)?

David Natan is reported as a director of Indaptus Therapeutics, Inc. and is not listed as an officer or 10% owner in this Form 3.

What transaction information is included in this INDP Form 3 filing?

The Form 3 is an initial ownership report and indicates a holding position with 0.0000 shares beneficially owned following the reported date.

Are there any derivative securities reported for the INDP director?

No. The section for Derivative Securities Beneficially Owned contains no entries, indicating no reportable derivative positions.